Merck Sharp + Dohme Corp.

Basilea Pharmaceutica Ag

Norgine Bv

Elexopharm Gmbh

Rohit Saxena

Bheemashankar A Kulkarni

Yusheng Xiong

Clare London

Scott B Hoyt

Amjad Ali

Rajagopal Bakthavatchalam

Michael Man-Chu Lo

Martin Eberle

Timothy J Henderson

Felix Bachmann

Rolf Wolfgang Hartmann

Min K Park

Emma Louise Carswell

Jerry Andrew Taylor

Jiaqiang Cai

Paul David Ratcliffe

Andrew Cooke

Swapan Kumar Samanta

Ralf Heim

Goutam Saha

Subho Roy

D Jonathan Bennett

Alessandro Strebel

Sudhir Srivastava

Chandregowda Venkateshappa

Lina Yin

Qingzhong Hu

John MacLean

Emmanuel Bey

Whitney Lane Petrilli

Rajendra Kristam

Vellarkad Viswanathan

Subir Kumar Sadhukhan

Manas Kumar Basu

Archana Gupta

Ajit Kumar Behera

Christopher Alexander Hewson

Sanjay Venkatachalapathi Kadnur

Sarkis Barret Kalindjian

Rajenda Kristam

Akila Parvathy Dharshinis

Mohd Zainuddin

Juluri Suresh

Bey; Emmanuel

Michael Lo

The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD). 

Compounds useful as CCR9 modulators

The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure. 

Aldosterone synthase inhibitors

This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase. 

The invention relates to novel substituted 2-(phenyl-, pyridyl- or pyrimidyl-carbonyl)-furanes and -thiophenes and related phenoxy/phenylthio-acetophenones and corresponding heterocyclic compounds, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of neoplastic diseases and autoimmune diseases, and a method for the treatment of such a diseases.

Aroylfuranes and aroylthiophenes

Growing community of inventors

Uttar Pradesh, India

Rohit Saxena